Monte Rosa Q2 FY26 net loss widens to $43.4 million; revenue falls 61.3% to $9 million

Reuters2026/08/06 11:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Monte Rosa Therapeutics posted a net loss of $43.4 million in Q2 2026, widening from a $12.3 million loss a year earlier.
Revenue fell 61% to $9 million, while R&D expenses climbed 56% to $48 million on higher MRT-8102 and other program spending.
Cash, cash equivalents, restricted cash, and marketable securities totaled $626 million as of June 30, down from $671.2 million as of March 31.
Completed enrollment and dosing in the MRT-8102 GFORCE-1 Phase 1 study in elevated CVD-risk subjects; readout is expected in H2 2026.
Activated the MODeFIRe-1 Phase 2 trial of MRT-2359 with apalutamide in mCRPC; Novartis activated a Phase 2a/b study of MRT-6160 in Sjögren's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Monte Rosa Q2 FY26 net loss widens to $43.4 million; revenue falls 61.3% to $9 million

You may also like

Crypto prices